With various acquisititions occurring in the wake of #JPM18 plus CAR T cell therapy being back in the news this morning following the proposed Juno acquisition by Celgene following on from the recent Kite/Gilead deal, not to mention some recent publications on the role of checkpoints in enhancing the technology, I wanted to explore a related area:
It’s time to talk about ICOS…
Before you think I’ve gone completely over to the dark side talking about blockchains, rest assured that we do not refer here to Initial Coin Offerings i.e. an unregulated means by which funds are raised for a new cryptocurrency venture, but rather to an inducible co-stimulator of T cells that is structurally and functionally related to CD28.
In short, it’s an immune stimulatory rather than inhibitory checkpoint target that is gaining attention of late and is something we are likely to hear a lot more about over the near term.
Related to this is highlighting up and coming biotechs in the IO space who are exploring novel targets beyond the obvious anti-PD(L)1 focus since we need to see what might happen with IO-IO combinations as a way to improve responses and outcomes such that more people with cancer can receive benefit from immunotherapy.
Here, we offer a look at a biotech active in this space to learn what their approach is and where their pipeline is going in the near to medium term future.